Loading clinical trials...

Combined Effect of tDCS and Motor or Cognitive Activity in Patients With Alzheimer's Disease | Clinical Trials | Clareo Health

TERMINATEDNA

Combined Effect of tDCS and Motor or Cognitive Activity in Patients With Alzheimer's Disease

Combined Effect of tDCS and Motor or Cognitive Activity in Patients With Alzheimer's Disease: A Proof-of-Concept Pilot Study

NCT06619795•Universita di Verona

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to evaluate the effectiveness of combining tDCS with motor or cognitive activities on cognitive functions in patients with AD. Second aim is to investigate if tDCS has a different impact if it is combined with motor or cognitive activities.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Mini Mental State Examination (MMSE) major or equal to 15;
•good level of compliance;
•acetylcholinesterase inhibitor treatment (e.g., donepezil, rivastigmine);
•no modifications of medication during the last four months.

Exclusion Criteria

•behavioral disorders (e.g., aggressiveness);
•alcohol abuse;
•orthopedic pathology with risk of falls to the ground;
•respiratory pathology;
•severe auditory or visual deficits uncorrected;
•history of epileptic fits;
•anti-epileptic medication;
•metallic body implants; pacemaker;
•psychiatric, neurologic, systemic or metabolic disorders.

Locations (1)

Mons. A. Mazzali Foundation

Mantova, Italy

Key Dates

Start Date

June 1, 2018

Primary Completion Date

December 31, 2019

Completion Date

December 31, 2019

Last Updated

October 15, 2024

Enrollment

ACTUAL participants

Conditions

Alzheimer Disease (AD)

Interventions

Anodal tDCS

DEVICE

Sham tDCS

DEVICE

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

NCT07234695

Down SyndromeDown Syndrome (DS)+8 more

View study

RECRUITINGNA

Alzheimer's Disease Treated With Vagus Nerve Stimulation

NCT06923007

Alzheimer Disease (AD)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 15, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Combined Effect of tDCS and Motor or Cognitive Activity in Patients With Alzheimer's Disease

Inclusion Criteria

Exclusion Criteria

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

Alzheimer's Disease Treated With Vagus Nerve Stimulation

Effects on the Olfactory Epithelium and the Olfactory Nerve From Exposure to Diesel Exhaust

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research

Impact of Musical Therapeutic Intervention on Depression in Dementia Patients and Caregiver Burden